Determinants of quality of care in patients with Thrombotic Thrombocytopenic Purpura (TTP) in Germany and the influence of rapid diagnostic facilities

Recruiting

• Conditions: M31.1; Thrombotic microangiopathy

• Registration Number: DRKS00024678
• Lead Sponsor: Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

•Patients at least 18 years old
•Signed consent form
•Patients with suspected TTP and planned ADAMTS13 activity test and PLASMIC Score > 4 (intermediate to high risk)
•Patients with recurrent TTP episode and planned ADAMTS13 activity test

Exclusion Criteria

•No signed consent form
•Patient < 18 years
•Patients with suspected TTP and PLASMIC Score = 4

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of TTP-positive patients of suspected TTP-cases

Secondary Outcome Measures

Name	Time	Method
umber of TTP-negative patients of suspected TTP cases Patienten <br>time from first symptoms/clinical presentation to diagnosis (ADAMTS 13 activtiy test result) /time from blood sample collection to diagnosis <br><br>therapy course (number of PEX, duration of immunosuppression/caplacizumab therapy, duration of ICU/hospital stay)<br><br>Outcome (morbidity, rezidive, mortality, related-Adverse Events) <br><br>Age, gender<br><br>further data in course: diagnosis (TTP [acquired, congenital], HUS, others), platelet number, ADAMTS13-activity, ADAMTS13 inhibitor, PLASMIC Score